Serum N-telopeptide of type I collagen and bone alkaline phosphatase and their relationship in patients with non-small cell lung carcinoma and bone metastases. Preliminary results

Anticancer Research

Volumn 31, Issue 11, 2011, Pages 3879-3881

  Lumachi, Franco ^a   Marino, Filippo ^a   Fanti, Giovanni ^b   Chiara, Giordano B ^b   Basso, Stefano M M ^b  

^a UNIVERSITY OF PADOVA   (Italy)

^b SM degli Angeli Hospital   (Italy)

Author keywords

BAP; Bone alkaline phosphatase; Bone metastases; Bone remodeling markers; Lung cancer; N telopeptide of type I collegen; Non small cell lung cancer; NTx

Indexed keywords

ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; TUMOR MARKER;

ADULT; AGE DISTRIBUTION; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE METASTASIS; BONE REMODELING; CANCER DIAGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; OSSIFICATION; OSTEOLYSIS; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

AGED; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BONE NEOPLASMS; BONE REMODELING; BONE RESORPTION; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; COLLAGEN TYPE I; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PEPTIDES; PROGNOSIS;

EID: 83055175099     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Fisseler-Eckhoff A: Prognostic factors in histopathology of lung cancer. Front Radiat Ther Oncol 42: 1-14, 2010.
2. Coleman RE: Skeletal complications of malignancy. Cancer 80: 1588-1594, 1997.
3. Kaira R, Murakami H, Kaira K, Takahashi T, Tsuya A, Nakamura Y, Naito T, Endo M and Yamamoto N: N-Telopeptide of type I collagen is useful for monitoring therapeutic response in non-small cell lung cancer patients with bone metastases. Int J Clin Oncol 15: 484-488, 2010.
4. Strewler GJ: Humoral manifestations of malignancy. In: Basic & Clinical Endocrinology. Greenspan FS and Strewler GJ (eds.). Stamford, CT, Appleton Lange, pp. 741-752, 1997.
5. Lumachi F, Brunello A, Roma A and Basso U: Cancer-induced hypercalcemia. Anticancer Res 29: 1551-1556, 2009.
6. Fujimoto R, Higashi T, Nakamoto Y, Hara T, Lyshchik A, Ishizu K, Kawashima H, Kawase S, Fujita T, Saga T and Togashi K: Diagnostic accuracy of bone metastases detection in cancer patients: comparison between bone scintigraphy and whole-body FDG-PET. Ann Nucl Med 20: 399-408, 2006. (Pubitemid 44259805)
7. Nishizawa Y, Nakamura T, Ohta H, Kushida K, Gorai I, Shiraki M, Fukunaga M, Hosoi T, Miki T, Chaki O, Ichimura S, Nakatsuka K and Miura M: Committee on the Guidelines for the Use of Biochemical Markers of Bone Turnover in Osteoporosis Japan Osteoporosis Society: Guidelines for the use of biochemical markers of bone turnover in osteoporosis (2004). J Bone Miner Metab 23: 97-104, 2005.
8. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917, 2010.
9. Carolan H, Sun AY, Bezjak A, Yi QL, Payne D, Kane G, Waldron J, Leighl N, Feld R, Burkes R, Keshavjee S and Shepherd F: Does the incidence and outcome of brain metastases in locally advanced non-small cell lung cancer justify prophylactic cranial irradiation or early detection ? Lung Cancer 49: 109-115, 2005. (Pubitemid 40798099)
10. D'Addario G and Felip E; ESMO Guidelines Working Group. Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 19(suppl 2): ii39-ii40, 2008.
11. Tankó LB, Karsdal MA, Christiansen C and Leeming DJ: Biochemical approach to the detection and monitoring of metastatic bone disease: What do we know and what questions need answers? Cancer Metastasis Rev 25: 659-668, 2006. (Pubitemid 46071870)
12. Liu T, Xu JY, Xu W, Bai YR, Yan WL and Yang HL: Fluorine-18 deoxyglucose positron-emission tomography, magnetic resonance imaging and bone scintigraphy for the diagnosis of bone metastases in patients with lung cancer: Which one is the best? A meta-analysis. Clin Oncol 23: 350-358, 2011.
13. Takenaka D, Ohno Y, Matsumoto K, Aoyama N, Onishi Y, Koyama H, Nogami M, Yoshikawa T, Matsumoto S and Sugimura K: Detection of bone metastases in non-small cell lung cancer patients: comparison of whole-body diffusion-weighted imaging (DWI), whole-body MR imaging without and with DWI, whole-body FDG-PET/CT, and bone scintigraphy. J Magn Reson Imaging 30: 298-308, 2009.
14. Song JW, Oh YM, Shim TS, Kim WS, Ryu JS and Choi CM: Efficacy comparison between (18)F-FDG PET/CT and bone scintigraphy in detecting bony metastases of non-small-cell lung cancer. Lung Cancer 65: 333-338, 2009.
15. Lumachi F, Brunello A, Roma A and Basso U: Medical treatment of malignancy-associated hypercalcemia. Curr Med Chem 15: 415-421, 2008. (Pubitemid 351266947)
16. Costa L, Demers LM, Gouveia-Oliveira A, Schaller J, Costa EB, de Moura MC and Lipton A: Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status. J Clin Oncol 20: 850-856, 2002. (Pubitemid 34111395)
17. Rajpar S, Massard C, Laplanche A, Tournay E, Gross-Goupil M, Loriot Y, Di Palma M, Bossi A, Escudier B, Chauchereau A and Fizazi K: Urinary N-telopeptide (uNTx) is an independent prognostic factor for overall survival in patients with bone metastases from castration-resistant prostate cancer. Ann Oncol 21: 1864-1869, 2010.
18. Ebert W, Muley TH, Herb KP and Schmidt-Gayk H: Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients. Anticancer Res 24: 3193-3202, 2004.
19. Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S Jr, Olak J, Stover D, Strawn JR, Turrisi AT and Somerfield MR; American Society of Clinical Oncology: American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 22: 330-353, 2004. (Pubitemid 41095099)
20. D'Addario G, Früh M, Reck M, Baumann P, Klepetko W and Felip E; ESMO Guidelines Working Group. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5): v116-v119, 2010.
21. Aruga A, Koizumi M, Hotta R, Takahashi S and Ogata E: Usefulness of bone metabolic markers in the diagnosis and follow-up of bone metastasis from lung cancer. Br J Cancer 76: 760-764, 1997. (Pubitemid 27379743)
22. Kobayashi T, Gabazza EC, Taguchi O, Risteli J, Risteli L, Kobayashi H, Yasui H, Yuda H, Sakai T, Kaneda M and Adachi Y: Type I collagen metabolites as tumor markers in patients with lung carcinoma. Cancer 85: 1951-1957, 1999. (Pubitemid 29202769)
23. Izumi M, Nakanishi Y, Takayama K, Kimotsuki K, Inoue K, Wataya H, Minami T and Hara N: Diagnostic value of bone-turnover metabolites in the diagnosis of bone metastases in patients with lung carcinoma. Cancer 91: 1487-1493, 2001. (Pubitemid 32319259)